Dawn E Quelle

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1809265/publications.pdf

Version: 2024-02-01

47 4,097 23 47 papers citations h-index g-index

51 51 51 5331 all docs docs citations times ranked citing authors

| # | Article | IF | Citations |
|----|---|------|-----------|
| 1 | Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19. Cell, 1997, 91, 649-659. | 13.5 | 1,519 |
| 2 | Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene, 1997, 15, 203-211. | 2.6 | 527 |
| 3 | Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function. Molecular and Cellular Biology, 2005, 25, 1258-1271. | 1.1 | 264 |
| 4 | The t(8;21) fusion protein, AML1–ETO, specifically represses the transcription of the p14ARF tumor suppressor in acute myeloid leukemia. Nature Medicine, 2002, 8, 743-750. | 15.2 | 258 |
| 5 | p53 Acetylation: Regulation and Consequences. Cancers, 2015, 7, 30-69. | 1.7 | 256 |
| 6 | Large-Scale Molecular Comparison of Human Schwann Cells to Malignant Peripheral Nerve Sheath Tumor Cell Lines and Tissues. Cancer Research, 2006, 66, 2584-2591. | 0.4 | 191 |
| 7 | ARF Function Does Not Require p53 Stabilization or Mdm2 Relocalization. Molecular and Cellular Biology, 2002, 22, 196-206. | 1.1 | 116 |
| 8 | Cyclin G1 has growth inhibitory activity linked to the ARF-Mdm2-p53 and pRb tumor suppressor pathways. Molecular Cancer Research, 2003, 1, 195-206. | 1.5 | 99 |
| 9 | Development and translational imaging of a TP53 porcine tumorigenesis model. Journal of Clinical Investigation, 2014, 124, 4052-4066. | 3.9 | 92 |
| 10 | Respiratory Syncytial Virus Decreases p53 Protein to Prolong Survival of Airway Epithelial Cells. Journal of Immunology, 2007, 179, 2741-2747. | 0.4 | 64 |
| 11 | D-Type Cyclins and Their Cyclin-dependent Kinases: G1 Phase Integrators of the Mitogenic Response. Cold Spring Harbor Symposia on Quantitative Biology, 1994, 59, 11-19. | 2.0 | 58 |
| 12 | A porcine model of neurofibromatosis type 1 that mimics the human disease. JCI Insight, 2018, 3, . | 2.3 | 44 |
| 13 | ARF Directly Binds DP1: Interaction with DP1 Coincides with the G1 Arrest Function of ARF. Molecular and Cellular Biology, 2005, 25, 8024-8036. | 1.1 | 41 |
| 14 | Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. Clinical Cancer Research, 2020, 26, 2011-2021. | 3.2 | 40 |
| 15 | Identification of Novel ARF Binding Proteins by Two-Hybrid Screening. Cell Cycle, 2006, 5, 642-647. | 1.3 | 38 |
| 16 | A Novel Nuclear Interactor of ARF and MDM2 (NIAM) That Maintains Chromosomal Stability. Journal of Biological Chemistry, 2007, 282, 1322-1333. | 1.6 | 38 |
| 17 | RABL6A Is an Essential Driver of MPNSTs that Negatively Regulates the RB1 Pathway and Sensitizes Tumor Cells to CDK4/6 Inhibitors. Clinical Cancer Research, 2020, 26, 2997-3011. | 3.2 | 34 |
| 18 | RABL6A Promotes G1–S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent Manner. Cancer Research, 2014, 74, 6661-6670. | 0.4 | 32 |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers, 2021, 13, 5117. | 1.7 | 31 |
| 20 | CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 3018. | 1.8 | 30 |
| 21 | Identification of novel ARF binding proteins by two-hybrid screening. Cell Cycle, 2006, 5, 641-6. | 1.3 | 29 |
| 22 | The ARF Tumor Suppressor Inhibits Tumor Cell Colonization Independent of p53 in a Novel Mouse Model of Pancreatic Ductal Adenocarcinoma Metastasis. Molecular Cancer Research, 2011, 9, 867-877. | 1.5 | 26 |
| 23 | RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Genes and Cancer, 2013, 4, 273-284. | 0.6 | 26 |
| 24 | RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth. Journal of Clinical Investigation, 2019, 129, 1641-1653. | 3.9 | 25 |
| 25 | DNA Damage-Induced G 1 Arrest in Hematopoietic Cells Is Overridden following Phosphatidylinositol 3-Kinase-Dependent Activation of Cyclin-Dependent Kinase 2. Molecular and Cellular Biology, 2001, 21, 6113-6121. | 1.1 | 23 |
| 26 | Nuclear interactor of ARF and Mdm2 regulates multiple pathways to activate p53. Cell Cycle, 2014, 13, 1288-1298. | 1.3 | 23 |
| 27 | Immunohistochemical Markers for Prospective Studies in Neurofibromatosis-1 Porcine Models. Journal of Histochemistry and Cytochemistry, 2017, 65, 607-618. | 1.3 | 21 |
| 28 | Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities. Experimental Cell Research, 2009, 315, 1326-1335. | 1.2 | 19 |
| 29 | Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations. Disease Markers, 2018, 2018, 1-7. | 0.6 | 13 |
| 30 | Longitudinal phenotype development in a minipig model of neurofibromatosis type 1. Scientific Reports, 2020, 10, 5046. | 1.6 | 13 |
| 31 | Myst2/Kat7 histone acetyltransferase interaction proteomics reveals tumour-suppressor Niam as a novel binding partner in embryonic stem cells. Scientific Reports, 2017, 7, 8157. | 1.6 | 12 |
| 32 | RABL6A, a Novel RAB-Like Protein, Controls Centrosome Amplification and Chromosome Instability in Primary Fibroblasts. PLoS ONE, 2013, 8, e80228. | 1,1 | 12 |
| 33 | Assessment of nociception and related quality-of-life measures in a porcine model of neurofibromatosis type 1. Pain, 2019, 160, 2473-2486. | 2.0 | 11 |
| 34 | Pdgfrα-Cre mediated knockout of the aryl hydrocarbon receptor protects mice from high-fat diet induced obesity and hepatic steatosis. PLoS ONE, 2020, 15, e0236741. | 1.1 | 11 |
| 35 | NIAM-Deficient Mice Are Predisposed to the Development of Proliferative Lesions including B-Cell Lymphomas. PLoS ONE, 2014, 9, e112126. | 1.1 | 7 |
| 36 | Prognostic and therapeutic value of the Hippo pathway, RABL6A, and p53-MDM2 axes in sarcomas. Oncotarget, 2021, 12, 740-755. | 0.8 | 7 |

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner. International Journal of Molecular Sciences, 2021, 22, 5367. | 1.8 | 7 |
| 38 | Phosphorylatable and epitope-tagged human erythropoietins: Utility and purification of native baculovirus-derived forms. Protein Expression and Purification, 1992, 3, 461-469. | 0.6 | 6 |
| 39 | Combination therapies for MPNSTs targeting RABL6A-RB1 signaling. Oncotarget, 2021, 12, 10-14. | 0.8 | 5 |
| 40 | Generation and Characterization of Monoclonal Antibodies to NIAM: A Nuclear Interactor of ARF and Mdm2. Hybridoma, 2008, 27, 159-166. | 0.5 | 4 |
| 41 | Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis. Scientific Reports, 2021, 11, 10252. | 1.6 | 4 |
| 42 | RABL6A Promotes Pancreatic Neuroendocrine Tumor Angiogenesis and Progression In Vivo. Biomedicines, 2021, 9, 633. | 1.4 | 4 |
| 43 | Utility of CD138/syndecan-1 immunohistochemistry for localization of plasmacytes is tissue-dependent in B6 mice. BMC Research Notes, 2022, 15, . | 0.6 | 4 |
| 44 | Porcine cancer models for translational oncology. Molecular and Cellular Oncology, 2014, 1, e969626. | 0.3 | 3 |
| 45 | Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo. Neuro-Oncology Advances, 2022, 4, vdac047. | 0.4 | 3 |
| 46 | ARF sees $Pdgfr\hat{l}^2$ through the miR. Cell Cycle, 2014, 13, 1520-1521. | 1.3 | 2 |
| 47 | Validating indicators of CNS disorders in a swine model of neurological disease. PLoS ONE, 2020, 15, e0228222. | 1.1 | 2 |